1. Highlight the under- recognized risk of stroke and/or inadequate prophylaxis in patients with atrial fibrillation and the associated morbidity, mortality, and cost burdens.
2. Discuss strategies to incorporate clinical guidelines and quality measures into patient care to optimize outcomes of anticoagulation therapy.
3. Discuss current and potential new challenges and opportunities in stroke prevention in atrial fibrillation.
4. Describe the multifaceted role of thrombin and its contribution to the underlying pathophysiology that results in thromboembolic events.
5. Enhance awareness and knowledge of current clinical and pharmacoeconomic research that adds to the body of scientific evidence and contributes to the care of patients with atrial fibrillation.
6. Develop strategies to improve communication between HCPs and their patients/caregivers about the benefits and risks of anticoagulation therapy.

1. Describe the mechanisms of action and clinical data describing the safety and efficacy of available and emerging therapies including incretin-based therapies in T2DM patients with microvascular and/or macrovascular complications. 
2. Outline the morbidity, mortality and cost burdens that result from inadequate management of T2DM and its resultant complications in diverse populations (race, ethnicity, gender and age etc).
3. Describe the role of aggressive, multifaceted approaches to attaining treatment goals including glycemic control and controlling weight, in relation to microvascular and/or macrovascular complications.
4. Enhance awareness of risk factors for declining renal function in at-risk patients with T2DM and emphasize the importance of early recognition and diagnosis of renal impairment and appropriate glycemic management in such patients.
5. Discuss strategies to align practice guidelines and consensus recommendations with current standards of care and to apply these appropriately for the care of patients with T2DM to optimize clinical outcomes.
6. Discuss new models of care in the management of T2DM which may assist providers in delivering improved patient care and educate patients on the importance of self-management of their disease.

1. Describe the extent and impact of medication therapy management (MTM) services on patient outcomes.
2. Discuss the role of quality improvement activities and services, such as pay for performance programs, patient-centered care models and medical informatics approaches in improving patient care.
3. Improve clinical competencies and provide counseling to patients in emerging practice models.
4. Recognize pharmaceutical care models that maximize collaborative practice opportunities, support evidenced based medicine, and demonstrate the pharmacists’ clinical value on the patient care team.
5. Review factors that enhance patient compliance, adherence and persistence with pharmacologic therapy and implement strategies to improve patient self-management of chronic disease.
6. Define the specific role of medication usage, including drug interactions, in special populations.

1. Further understanding of the pathiophysiology of immunologic diseases as well as current and emerging immunotherapeutic interventions.

(Please note: If you are seeking support for activities related to Virologic diseases (including HIV and HCV) or Oncology, please select one of these therapeutic categories for your application.

1. Increase knowledge among Pulmonologists, Interventional Radiologists, and Pathologists of the importance of EGFR mutation testing for subsequent management of NSCLC patients.
   • Improve understanding among Pulmonologists and Interventional Radiologists of need to acquire an adequate amount of tissue for EGFR molecular testing at time of the initial biopsy of lesions that may be NSCLC.
   • Improve understanding of the value of testing initial biopsy specimens for EGFR mutations among Pulmonologists, Interventional Radiologists, and Pathologists.
2. Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations to optimize therapeutic strategies.
   • Improve clinicians’ and pathologists’ knowledge of gene mutations and the utility of biomarker analysis in targeted treatment approaches to improve patient outcomes.
3. Describe mechanisms for resistance to inhibition of molecular signaling pathways and the durability of response of approved and investigational pathway inhibitors.
4. Enhance clinicians’ knowledge of signaling pathways in the development and progression of NSCLC and the consequences of dysregulation.
5. Increase clinicians’ knowledge and appropriate application of evidence-based clinical data in selection of therapeutic options for the management of solid tumors (including NSCLC, breast, ovarian, and head and neck cancer).
   • Understand how safety and tolerability of treatment may impact patient outcomes
6. Enhance clinicians’ understanding of the roles of proangiogenic signaling pathways in the development and progression of NSCLC 
   • Describe the impact of interactions between growth factors and their receptors on cellular proliferation, migration, differentiation, and cellular survival.
7. Improve clinicians’ knowledge of research discussing clinical outcomes in advanced/metastatic NSCLC when inhibiting multiple proangiogenic signaling pathways.
   • Improve clinicians’ awareness of data discussing antiangiogenic therapies for NSCLC in combination with standard chemotherapy
8. Improve early detection and early intervention efforts for patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
9. Expand understanding of tumor biology, prognosis, and current therapeutic options for patients with HNSCC
10. Increase understanding of ongoing clinical research for the treatment of patients with HNSCC

1. Increase healthcare providers' awareness of emerging scientific knowledge of cell cycle regulation.
2. Increase healthcare providers' knowledge of the potential role of cell cycle inhibitors in the treatment of Acute Myeloid Leukemia (AML).
3. Improve healthcare providers' identification of adult patients who may benefit from non-intensive therapy for AML.
4. Increase healthcare providers' knowledge of established and investigational therapeutic options for AML patients ineligible for intensive therapy.

1. Diagnosis and Treatment of COPD: Improve the knowledge and skills required by healthcare providers to identify correctly patients at risk for COPD, understand the role of population screeners, and the appropriate diagnosis and management of COPD patients using non-pharmacologic and pharmacologic treatment.
2. Exercise and Activity in COPD: Educate on the relevance of sustaining physical activity in patients with COPD and the impact on patient outcomes.
3. Diagnosis and Management of COPD with Co-Morbidities: Educate HCPs on the diagnosis and management of patients with COPD who have multiple co-morbidities.
4. COPD Pathophysiology: Increase the understanding of COPD pathophysiology, including the cholinergic, sympathomimetic, and inflammatory components, and the rationale for use of therapeutic agents with different mechanisms of action.
5. Understanding the Impact of Exacerbations: Educate HCPs on the recognition of COPD exacerbations, and the associated clinical impact, and relevant management strategies.
6. Patient Education: Increase patient awareness and knowledge of COPD diagnosis and treatment.
7. Patient Education: Increase the knowledge and skills of patients on the proper use of a variety of currently available inhalers.
8. Clinician Inhaler Technique Education: Educate clinicians and allied healthcare providers (MD, DO, NP, PA, RT, and Pharmacists) on effective methods for training patients to use different types of inhalers and the importance of patient confidence and accuracy.
9. Regular Patient Counseling: Increase clinician’s and allied healthcare providers’ (MD, DO, NP, PA, RT, and Pharmacists) knowledge of the rationale for conducting scheduled technique checks with their patients.

1. Improve understanding of IPF epidemiology and patient outcomes attributable to under-diagnosis and/or mis-diagnosis and the need for shorter time to diagnosis.
2. Increase kinowledge and awareness of IPF among HCPs regarding pathophysiology, and apropriate diagnosis testing for IPF disease management.
3. Increase healthcare providers' knowledge and application of new evidence-based guidelines (ATS/ERS/JRS/ALAT) for care of Idiopathic Pulmonary Fibrosis patients.

1. Improve healthcare provider's knowledge of underserved risk groups associated with chronic HCV infection and need to improve screening and diagnosis.
2. Improve healthcare providers' and patients' awareness and knowledge of the goals of treatment for patients with chronic HCV infection and co-morbidities with HCV (e.g. HIV).
3. Ensure healthcare providers' and patients' awareness of the current standard of care of chronic HCV infection and evolving approaches for potential future care and treatment options.

1. Enhance patient knowledge regarding the management and treatment of HIV.
2. Improve the clinicians' ability to recognize and understand important differences among HIV patient types and to identify appropriate communication methods and management practices.